Diagnostic stocks scramble for new growth in India as Covid gains halve
Surging healthcare spending and demand for Covid tests led to multifold share-price gains for pathology firms globally during the pandemic.
By Bloomberg |
BCCL
The tumble in Indian lab stocks has accelerated since the start of the year after disappointing results.
India’s listed clinical laboratories are looking for new sources of growth to fuel investor interest after seeing their massive coronavirus-fueled stock rallies more than halved in recent months.
Surging healthcare spending and demand for Covid tests led to multifold share-price gains for pathology firms globally during the pandemic. Those gains have started to fade as outbreaks ease and countries look to reopen, while concerns over higher interest rates have sparked a flight from risky investments including biotech.
The tumble in Indian lab stocks has accelerated since the start of the year after disappointing results. The nation’s longest-listed pathology company Thyrocare Technologies Ltd. posted lower revenue for the December quarter, hurt by reduced need for Covid-related tests, while larger peers Metropolis Healthcare Ltd. and Dr Lal PathLabs Ltd. missed analysts’ profit estimates.
“The outlook for laboratory stocks is muted,” said Kranthi Bathini, a strategist at Mumbai-based WealthMills Securities Pvt. “The companies now need to focus on growth from non-Covid streams.”
India has managed to control the recent outbreak, while testing capacity has been expanded significantly, Bathini noted. He said the companies have looked to expand through mergers and acquisitions, announcing deals when their stocks were at peak valuations.
Metropolis and Dr Lal both announced acquisitions of smaller players last year, looking to move into new fields. API Holdings Ltd., which owns the health-care brand PharmEasy and has announced plans to go public, last year acquired a two-thirds stake in Thyrocare from its founders.
ADVERTISEMENT
Bajaj Auto, L&T among 7 stocks that may help you wade through volatility
1/8
Volatility has become a consistent theme in the current market environment. With a number of uncertain headwinds, making money has become tough but not impossible. There are several stocks that have given breakouts. Below are seven names that analysts recommend:
Volatility has become a consistent theme in the current market environment. With a number of uncertain headwinds, making money has become tough but not impossible. There are several stocks that have..
Read More
The stock found support at its 20-week SMA and has recently been consolidating in a range between Rs 5,000-5,290 levels. This week, the stock broke out of this range on the back of above average volumes. This augurs well for the uptrend to continue. Technical indicators are giving positive signals as the stock trades above its key short term and intermediate term moving averages. Momentum readings like the 14-day RSI are in a rising mode and not overbought and the Relative Strength Comparative indicator too has broken out of a range. The analyst, therefore, recommends a buy on Bajaj Holdings between Rs 5,350-5,390. A stop loss is suggested at Rs 5,200, while target is at Rs 5,750. (Subash Gangadharan, Senior Technical and Derivative Analyst, HDFC Securities)
The stock found support at its 20-week SMA and has recently been consolidating in a range between Rs 5,000-5,290 levels. This week, the stock broke out of this range on the back of above average volu..
Read More
Technical indicators are giving positive signals as the stock is trading above its 20-day and 50-day SMA. Momentum readings like the 14-day RSI too are in a rising mode and not overbought, which implies potential for further upsides. The stock closed above the mid band of the 20-day Bollinger Band, which is a sign of strength. The analyst expects the stock to move up further and take out its recent life highs in the coming sessions. Recommend a buy between Rs 3,115-3,135 levels. Keep a stop loss at Rs 2,930 for a target of Rs 3,500.
(Subash Gangadharan, Senior Technical and Derivative Analyst, HDFC Securities)
Technical indicators are giving positive signals as the stock is trading above its 20-day and 50-day SMA. Momentum readings like the 14-day RSI too are in a rising mode and not overbought, which impl..
Read More
After a medium-term correction, the stock took support near Rs 1,800 and reversed sharply. The stock has formed a promising reversal formation which indicates strong possibility of fresh uptrend from current levels. Currently, the stock is trading near a 50- and 20-day SMA, it is also trading near an important retracement support level. The short term texture of the chart suggests further upside from current levels. Rs 1,815 would be the immediate support level for positional traders, above which it could rally till Rs 2,010.
(Shrikant Chouhan, Head of Equity Research (Retail) at Kotak Securities)
After a medium-term correction, the stock took support near Rs 1,800 and reversed sharply. The stock has formed a promising reversal formation which indicates strong possibility of fresh uptrend from..
Read More
On the daily and intraday charts, the stock consistently formed a higher bottom formation which is broadly positive. In addition, after a long time, it succeeded to close above Rs 3,600 and on weekly charts it has formed a long bullish candle which supports the short term uptrend. For trend following traders, Rs 3,505 would be the sacrosanct support level, above which Bajaj Auto will move up to Rs 3,890.
(Shrikant Chouhan, Head of Equity Research (Retail) at Kotak Securities)
On the daily and intraday charts, the stock consistently formed a higher bottom formation which is broadly positive. In addition, after a long time, it succeeded to close above Rs 3,600 and on weekly..
Read More
After a promising breakout, the stock witnessed some profit booking at higher levels. However, the short-term structure of Sun Pharma is still on to the bullish side. Currently, it is trading near its 20-day SMA and important retracement level. Unless it is trading below Rs 833, positional traders can retain an optimistic stance and look for a target of Rs 925. Fresh buying can be considered now and on dips, if any, between Rs 865 and Rs 850 levels with a stop loss below Rs 833. (Shrikant Chouhan, Head of Equity Research (Retail) at Kotak Securities)
After a promising breakout, the stock witnessed some profit booking at higher levels. However, the short-term structure of Sun Pharma is still on to the bullish side. Currently, it is trading near it..
Read More
With Friday’s up move, the stock has confirmed a bullish breakout from the ‘V’ pattern due to its steep rise. This pattern has a bullish implication when accompanied with higher-than-average volumes. All these requirements do meet here and hence, we recommend buying this stock on a small decline towards Rs 1,240-1,235 for a trading target of Rs 1,310. A stop loss can be placed at Rs 1,212.
(Sameet Chavan, Angel One)
With Friday’s up move, the stock has confirmed a bullish breakout from the ‘V’ pattern due to its steep rise. This pattern has a bullish implication when accompanied with higher-than-average volumes...
Read More
In the last three trading sessions, all of a sudden, the tide turned upwards for this stock. Before anyone could even realize, prices have soared more than 20 per cent in such a short span. More importantly, if we take a glance at the volume activity, we can see some abnormal volumes in this counter, which is an indication of immense buying interest. Since the stock has moved quite a lot, we recommend buying this stock on a decline towards Rs 345-340 for a near term target of Rs 392. A stop loss can be placed at Rs 318.
(Sameet Chavan, Angel One)
In the last three trading sessions, all of a sudden, the tide turned upwards for this stock. Before anyone could even realize, prices have soared more than 20 per cent in such a short span. More impo..
